IP Library Granted Patent US 8,685,938
Granted Patent B2
US 8,685,938 · App. 13/082,790 · Granted Apr 1, 2014

Methods to enhance T-cell mediated immune response

Inventors: Jorg J Goronzy (Palo Alto, CA); Cornelia Weyand (Palo Alto, CA); Mingcan Yu (Palo Alto, CA)
Assignees: The Board of Trustees of the Leland Stanford Junior University; The United States of America as Represented by the Department of Veterans Affairs
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,685,938
App. No.
13/082,790
Granted
Apr 1, 2014
Kind
B2
Abstract

The present invention provides methods for restoring or enhancing T cell mediated immune response in individuals of middle and advanced age.

Claims (13)

1. A method of restoring T cell-mediated immune response to an exogenous immunogen in an individual whose immune response is compromised, the method comprising: administering a pharmaceutical composition comprising a modulator of activity or expression of dual specificity phosphatase 4 to said individual in a therapeutically effective amount and within a predetermined time period before, during or after administration of said immunogen, whereby the modulator of activity or expression is an antisense polynucleotide capable of hybridizing to SEQ ID NO:9.

2. The method of claim 1 , wherein said individual is of advanced age.

3. The method of claim 1 , wherein said individual is of middle age.

4. The method of claim 1 , wherein said modulator is a small molecule pharmacological inhibitor of said dual specificity phosphatase 4.

5. The method of claim 1 , wherein said modulator down-regulates the expression of said dual specificity phosphatase 4.

6. The method of claim 1 , wherein said administration is oral, systemic or local.

7. A method of enhancing T cell-mediated immune response to an exogenous immunogen in an individual whose immune response is compromised, the method comprising: administering a pharmaceutical composition comprising a modulator of activity or expression of at least one dual specificity phosphatase to said individual in a therapeutically effective amount and within a predetermined time period before, during or after administration of said immunogen, whereby the modulator of activity or expression is an antisense polynucleotide capable of hybridizing to SEQ ID NO:9.

8. The method of claim 7 , wherein said individual is of advanced age.

9. The method of claim 7 , wherein said individual is of middle age.

10. The method of claim 7 , wherein said dual specificity phosphatase is dual specificity phosphatase 4.

11. The method of claim 7 , wherein said modulator is a small molecule pharmacological inhibitor of said dual specificity phosphatase 4.

12. The method of claim 7 , wherein said modulator downregulates the expression of said dual specificity phosphatase 4.

13. The method of claim 7 , wherein said administration is oral, systemic or local.

Assignments (3)
CONFIRMATORY LICENSE Recorded Dec 3, 2014
From: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034535/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2014
From: WEYAND, CORNELIA; GORONZY, JORG J
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY; THE U.S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Reel/Frame 032879/0467 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2014
From: YU, MINGCAN; LI, GUANGJIN
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 032788/0531 →
Continuity (3)
Provisional Application 61322297 · Apr 9, 2010
Provisional Application 61358398 · Jun 24, 2010
Related Publication 20110281932A1 · Nov 17, 2011